Recipharm releases first serialised products to Europe
Advertisement
Recipharm has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden.
In 2016 Recipharm committed to invest 40 million euros in preparing its facilities for the European Falsified Medicines Directive (EU FMD). The release of its first batch of serialised medicine to the European market is a significant milestone in the CDMO's journey towards compliance with the new regulation.
Recipharm’s other facilities across Europe will also be ready to release fully serialised products to Europe by the end of the year, two months ahead of the EU FMD deadline in February 2019.
Recipharm has already delivered over 2.5 million serialised packs to markets where serialisation regulations are in place, including China, South Korea, Saudi Arabia and Turkey, as well as 500,000 packs to the US. The company is implementing the technologies of cloud network provider TraceLink and software and hardware providers SeaVision and Marchesini.
Staffan Widengren, director corporate projects and head of the global steering committee for Recipharm’s serialisation programme said: “Over recent years Recipharm has become known for leading the way in meeting the serialisation challenge. We are proud to have reached this milestone four months before the FMD deadline and anticipate that all our facilities will meet compliance by the end of the year.”
Recipharm is also serialising its customers’ products for free until February 2019 to ensure a seamless transition when the regulation comes into force.
Staffan added: “Recipharm is keen to aid companies in meeting compliance on time and ultimately help to create a safer global medicine supply.”
This news follows the launch of Recipharm’s standalone serialisation service, which allows pharmaceutical companies to benefit from its serialisation capabilities as a standalone service even if their products are not manufactured by the CDMO. This will ensure that companies that have not yet prepared for the upcoming FMD deadline have a way to achieve compliance in time.
As part of the service, Recipharm will add 2D codes, human readable text and tamper evidence to pre-packaged medicines.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Opening the way for global innovation in biotechnology - New agreement supports sharing, innovation and openness
ECETOC Task Force provides new insights - Toxicity testing of microparticles and poorly soluble liquids in the water environment
Merck Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
Restriction of hazardous substances in tattoo inks
Japan and Singapore Grant CRISPR Patents to Merck
What the Biden-Harris administration means for chemistry - The new administration has inherited a global pandemic and worsening climate change, among other science-related issues
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency
Chemical pollution threatens biodiversity - Scientists say more environmental pollutants should be considered in species protection
BioM and Munich Biotech Cluster celebrate its 25th anniversary - A quarter century of success in biotechnology
ECHA’s investigation finds toxic chemicals present in childcare products
Cancer treatment: Experts propose specific and suited guidelines for the use and regulation of artificial intelligence
